Vaccination Response Modulation With a Targeted Rapamycin Protocol Study
Key facts
- Who runs it
- Central Adelaide Local Health Network Incorporated
- Where
- Australia3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- May 2026
- Planned end
- Jul 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sirolimus (RAPAMUNE)
- Influenza vaccine (Sequiris Fluad Quad)
- RSV vaccine (Pfizer Abrysvo)
- Record updated
- 14 May 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy
- Aged >60 years
Who cannot take part
- Current use of immunosuppressive medications, including:; Oral steroid at a dose equivalent of 5 mg/day prednisolone or greater; Mycophenolate mofetil; Azathioprine; Calcineurin inhibitors; mTOR inhibitors
- Recent use of intravenous immunosuppressive medications (<6 months), including:; T-cell depleting agents (e.g. anti-thymocyte globulin); B-cell depleting agents (e.g. rituximab); Cyclophosphamide
- Has a history of problems with side-effects associated with sirolimus use including; Angioedema; Active/recent opportunistic infection; Current or prior interstitial lung disease, non-infectious pneumonitis, organising pneumonia, or pulmonary fibrosis; Clinically significant pleural effusion or pericardial effusion; Active non-healing wounds, chronic skin ulcers, or planned major surgery/procedures; Current malignancy or recent malignancy with high recurrence risk; Severe or uncontrolled hyperlipidaemia; History of rhabdomyolysis; Severe hepatic impairment
- Ongoing use of strong CYP3A4/P-gp inhibitors or inducers including; Inhibitors: Ketoconazole, Voriconazole, Itraconazole, Telithromycin, Clarithromycin; Inducers: Rifampicin, Rifabutin
- Recent infection (<6 months) with proven Influenza A, Influenza B, or RSV
- Known allergy to or intolerance of sirolimus (rapamycin) or the contents of the influenza or RSV vaccine
- Aged <60 years
- Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)
- Unable or unwilling to provide informed consent to participate in the trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will investigate dialysis recipients' responses to important vaccines.
Read full original descriptionShow less
Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.
The 4 groups in the trial
- ControlExisting treatment, for comparison
Influenza and RSV vaccination without additional treatment
Treatment: Influenza vaccine (Sequiris Fluad Quad) and RSV vaccine (Pfizer Abrysvo)
- Pre-vaccine sirolimus groupTreatment being tested
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks after completing sirolimus course.
Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)
- Peri-vaccine sirolimus groupTreatment being tested
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 1 week after commencing sirolimus course.
Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)
- Post-vaccine sirolimus groupTreatment being tested
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks prior to commencing sirolimus course.
Treatment: Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), and RSV vaccine (Pfizer Abrysvo)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Vaccination Response Modulation With a Targeted Rapamycin Protocol (VON TRAPP) Study
- Record updated
- 14 May 2026